Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Cytocom, Inc.
  6. News
  7. Summary
    CBLI   US23284M1009

CYTOCOM, INC.

(CBLI)
SummaryQuotesChartsNewsCalendarCompanyFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Nasdaq Halts Statera Biopharma, Inc.

08/25/2022 | 11:49am EST

NEW YORK, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in Statera Biopharma, Inc. (Nasdaq: STAB) at 11:01:52 A.M. Eastern Time for "additional information requested" from the company at a last sale price of $0.215.

Trading will remain halted until Statera Biopharma, Inc. has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Media Contact:

Sophia Weiss
sophia.weiss@nasdaq.com

NDAQO

 


Primary Logo

Source: Nasdaq, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
NASDAQ, INC. 0.03% 67.15 Delayed Quote.-4.08%
All news about CYTOCOM, INC.
11/15Statera Biopharma, Inc. : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
11/14STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
11/14Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months ..
CI
11/07Statera Biopharma : Material Agreement - Form 8-K
PU
11/07Statera Biopharma, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of..
AQ
11/07Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Sil..
CI
11/01Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding
CI
10/28STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
10/28Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
CI
10/27Statera Biopharma, Inc. : Other Events (form 8-K)
AQ
More news
Chart CYTOCOM, INC.
Duration : Period :
Cytocom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Michael Kevin Handley Chairman, President & Chief Executive Officer
Christopher Zosh VP, Chief Financial & Accounting Officer
Robert W. Buckheit Chief Technology Officer
James Mendolera Director-Information Technology
Allie Lopez Senior Director-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
CYTOCOM, INC.0.00%7
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918